Please login to the form below

Not currently logged in
Email:
Password:

arthritis

This page shows the latest arthritis news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

Fostamatinib was being developed as a treatment for rheumatoid arthritis by AstraZeneca (AZ), but the big pharma company returned rights to the drug in 2013 after disappointing phase III trials.

Latest news

  • AbbVie’s upadacitinib aces phase III trial AbbVie’s upadacitinib aces phase III trial

    AbbVie’ s upadacitinib aces phase III trial. Arthritis drug outperformed both placebo and Humira in the study. ... AbbVie’s JAK1 inhibitor upadacitinib has proved more effective than the company’s widely-used TNF blocker Humira in a phase III trial

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    Sandoz’Zessly, a biosimilar of J&J’s Remicade (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

  • Lilly drops Hanmi-partnered arthritis drug Lilly drops Hanmi-partnered arthritis drug

    Lilly drops Hanmi-partnered arthritis drug. Concludes that its BTK inhibitor is likely to be clinically ineffective. ... rheumatoid arthritis in Europe and after a delay has refiled the drug in the US, he said.

  • AbbVie reports more solid data for would-be psoriasis blockbuster AbbVie reports more solid data for would-be psoriasis blockbuster

    New drugs are starting to chip away at the dominance of AbbVie’s anti-TNF drug Humira (adalimumab) in psoriasis and other indications like rheumatoid arthritis, although it still dwarfs them ... data last year, and is also in pivotal trials for

  • Arthritis patient group launches interactive video initiative Arthritis patient group launches interactive video initiative

    Arthritis patient group launches interactive video initiative. NRAS hopes its Love Your Heart programme will lower CV risks in those with RA. ... A UK arthritis patient group has launched an interactive video programme that it hopes will help lower

More from news
Approximately 98 fully matching, plus 613 partially matching documents found.

Latest Intelligence

  • Finding the patient voice Finding the patient voice

    rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.

  • The good, the bad and the ugly The good, the bad and the ugly

    Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic

  • The tipping point The tipping point

    In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.

  • Mobile health and patient outcomes Mobile health and patient outcomes

    In a recent study in rheumatoid arthritis, patients saw pain as the key measure of treatment success, confounding the objective ‘clinical evidence’of improvement.

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    arthritis and Parkinson’s.

More from intelligence
Approximately 0 fully matching, plus 41 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Patient Perspective: Gout

    In our latest Patient Perspective interview, we talk to Graham Lewington, who has lived with this form of arthritis for over 25 years.

  • Getting personal with wearable tech

    Interestingly in July 2016, GlaxoSmithKline launched a rheumatoid arthritis study, called PARADE, and an iPhone app using Apple's ResearchKit, demonstrating the first time a drugmaker has used the open source

  • Living with RA Report

    Living with RA Report. Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.

  • Infographic: RA market snapshot

    Infographic: RA market snapshot. An overview of the RA biologic patient. Our RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents. Our analyses are based on 139, 984

  • Research Partnership publishes 2016 Living with RA reports

    Research Partnership publishes 2016 Living with RA reports. Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016. ... Living with RA is a quantitative study conducted online amongst 500 patients

More from PMHub
Approximately 7 fully matching, plus 24 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics